| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrol Dial Transplant (2000) 15: 3-9
© 2000 European Renal Association-European Dialysis and Transplant Association
Theoretical Aspects of Renal Replacement Therapy
Solute fluxes in different treatment modalities
Research Service, Veterans Affairs Medical Center, Salt Lake City and Departments of Internal Medicine and Bioengineering, University of Utah, Salt Lake City, Utah, USA
Abstract
The principles governing solute flux or transport in different artificial kidney treatment modalities are reviewed. Solute clearance profiles were calculated for identical artificial kidney membranes during haemodialysis, haemofiltration and haemodiafiltration. It was shown that the clearance of small solutes depends largely on the dialysate flow rate and is similar when using either haemodialysis or haemodiafiltration. In contrast, clearance of middle molecules, especially low-molecular-weight proteins, depends largely on convective transport induced by high ultrafiltration rates and is maximized when using either haemofiltration or haemodiafiltration. Optimal fluxes for both small solutes and middle molecules can be achieved by using postdilution haemodiafiltration.
Recent work has shown that use of the reduction in plasma concentration, even after normalization for changes in extracellular volume during therapy, is not an exact measure of ß2-microglobulin (and other low-molecular-weight proteins) clearance. It is proposed that ß2-microglobulin clearance be reported in future studies instead of the normalized reduction in ß2-microglobulin plasma concentration. Additional studies are necessary to determine the effects of postdialysis rebound on the calculated clearance for ß2-microglobulin and other high-molecular-mass uraemic toxins.
Notes
Correspondence and offprint requests to: J. K. Leypoldt, PhD, Dumke Building 535, University of Utah, Salt Lake City, UT 84112, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Ledebo and P. J. Blankestijn Haemodiafiltration--optimal efficiency and safety NDT Plus, November 5, 2009; (2009) sfp149v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. de Bie, B. van Dam, A. Gaasbeek, M. van Buren, L. van Erven, J. J. Bax, M. J. Schalij, T. J. Rabelink, and J. W. Jukema The current status of interventions aiming at reducing sudden cardiac death in dialysis patients Eur. Heart J., July 1, 2009; 30(13): 1559 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. McCloskey, J. Smyth, W. Marshall, and N. Leonard Octreotide scanning in the detection of metastatic renal cell carcinoma NDT Plus, October 1, 2008; 1(5): 369 - 370. [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. van der Weerd, E. L. Penne, M. A. van den Dorpel, M. P.C. Grooteman, M. J. Nube, M. L. Bots, P. M. ter Wee, and P. J. Blankestijn Haemodiafiltration: promise for the future? Nephrol. Dial. Transplant., February 1, 2008; 23(2): 438 - 443. [Full Text] [PDF]
|
|
|
|
|
|
E. Villar, P. Boissonnat, L. Sebbag, A. Hendawy, R. Cahen, P. Trolliet, M. Labeeuw, R. Ecochard, and C. Pouteil-Noble Poor prognosis of heart transplant patients with end-stage renal failure Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1383 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bayat, L. Frimat, N. Thilly, C. Loos, S. Briancon, and M. Kessler Medical and non-medical determinants of access to renal transplant waiting list in a French community-based network of care Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2900 - 2907. [Abstract] [Full Text] [PDF]
|
|